Currently, there are 333.93M common shares owned by the public and among those 271.61M shares have been available to trade.
The company’s stock has a 5-day price change of -5.14% and -70.20% over the past three months. IOVA shares are trading -77.57% year to date (YTD), with the 12-month market performance down to -84.51% lower. It has a 12-month low price of $1.65 and touched a high of $12.51 over the same period. IOVA has an average intraday trading volume of 12.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -42.20%, -48.15%, and -76.81% respectively.
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 62.86% of the company’s 333.93M shares outstanding.
It has a market capitalization of $554.33M and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.85% over the week and 8.74% over the month.
Earnings per share for the fiscal year are expected to increase by 10.19%, and 34.83% over the next financial year. EPS should grow at an annualized rate of 47.62% over the next five years, compared to 4.17% over the past 5-year period.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on May 16, 2025, with the firm’s price target at $2. Citizens JMP was of a view on May 09, 2025 that the stock is Mkt Perform, while UBS gave the stock Buy rating on October 24, 2024, issuing a price target of $17. Piper Sandler on their part issued Neutral rating on July 29, 2024.
